ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 07 4:00PM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
StayHumble StayHumble 6 minutes ago
💹GreenAcres Stores💹 launch $HCWC AnnualRevenue $74Million+💹 @healthiercmc
https://www.healthiercmc.com/news/2024/7/24/hcmc-announces-the-acquisition-of-greenacres-market-with-5-stores-located-in-kansas-and-oklahoma


https://static1.squarespace.com
HCWC
meixatech meixatech 7 minutes ago
Lippa has senior positions in 5 venture capital firms! It appears RSPI is well capitalized. The question is why Lippa has not elected to promote RSPI by announcing support through his capital firms RSPI?. Could it be that he purposedly put RSPI in EM? To accumulate its stock in the process? Coul
RSPI
wingtrade wingtrade 7 minutes ago
How is fmc pay connected?
FBEC
1vman 1vman 8 minutes ago
*****🟥🟥🟥 LOL ! now I am hearing 🟥nonsense🟥Kramer naked shorted DBMM

https://investorshub.advfn.com/uimage/uploads/2024/8/20/fpjzxkrammer.webp

ENOUGH SAID HUZZAH🤪 !!!
DBMM
StayHumble StayHumble 9 minutes ago
BUY low💹Sell HIGH💹$9.99 a Share🍀💹wow!!
MJNA
NorthPeak22 NorthPeak22 9 minutes ago
You're telling people to get a life for supporting something that has a direct impact on their investment, on a forum designed for people to talk about their investments. You're the one that needs to get a life. GFY has a very specific meaning, look it up if you need help. Also, you don't start sent
TGLO
IanFromSI IanFromSI 11 minutes ago
No emerging biotech that’s declared itself to be a going concern has ever been able to raise any capital.

I would be very surprised if RVNC were to become the first.

My guess is that RVNC has been trying left right and centre to either find another bidder or get some
RVNC
Dallas-Cowboys Dallas-Cowboys 11 minutes ago
Not a lot of catalysts coming tax selling and January effect 
NVDA
Heisgreater Heisgreater 12 minutes ago
You know webslinger these words you use to slander Kim are really shameful. We pray for Kim and his continuing success and what he's providing for us shareholders monetarily. This dark evil language you use against this man (who is doing what he can to bring about prosperity for shareholders) is sic
KBLB
Lime Time Lime Time 14 minutes ago
A lot of good tickers turning bullish into 2025. This was expected. The tables have turned. Once we hear from Sharp, this explodes.
GVSI
JonDoe1 JonDoe1 14 minutes ago
Per terms of the note "Clive" isn't allowed to hold more than 5% nor is he listed as a more than 5% shareholder. Also, there is no legal way for him to hold more than 5% without it being disclosed.
AABB
glenn1919 glenn1919 15 minutes ago
RLAY...............................................https://stockcharts.com/h-sc/ui?s=RLAY&p=D&yr=0&mn=2&dy=12&id=p84071410134
RLAY
CanItBThisEZ2Make CanItBThisEZ2Make 16 minutes ago
BEST SELLERS RANK (BSR) IS 256 61 Estimated Sold on Amazon Since OCT 1 - 4TH Quarter 2024
https://investorshub.advfn.com/uimage/uploads/2024/4/24/cnxttVOS_5G_GIF.gif
https://www.amazon.com/Vos-RDGL5GX55-B-01-VOS-5G-Dongle/dp/B0C66KHZLP

NOTE: In theory, when BSR Value Dec
SRMX
glenn1919 glenn1919 16 minutes ago
RLAY...................https://stockcharts.com/h-sc/ui?s=RLAY&p=W&b=5&g=0&id=p86431144783
RLAY
ergo sum ergo sum 17 minutes ago
Apparently only legislators and Healthcare executives can kill people but killing them is not allowed.
Acme Investments Acme Investments 17 minutes ago
Even if this bumps to .003.......I'll take it!! LOL 😂
JAMN
stockinspector stockinspector 18 minutes ago
You read all the fine print and signed the dotted lines just like the rest of us right?
That's why I call it whining. If you are still holding than it is all on you isn't it?
Side note - I did all of the above and feel great about it!
WDLF
cottonmather cottonmather 18 minutes ago
Silver Dragons. Silver breakout soon? 9 minutes. https://youtu.be/9OusQne1D20?si=X_vnsrBuSE2wqQWq
jimr1717 jimr1717 19 minutes ago
I would expect that you can move the tiny bid out of the way to dump another load and prop your bid back up to lessen your losses coming.

No one is Fooled by the CONdog96 🤡™ clown.

Can’t say I blame you. You have been bag holding for a long time
ATMH
skitahoe skitahoe 20 minutes ago
As most here know, I also have an investment in AVXL. In many ways it's a tale of two companies. One, AVXL has managed to stay very financially viable with roughly 4 years of funding available. While they're probably over a year behind NWBO in being considered for approval in Alzheimer's, both co
AVXL NWBO
haha11 haha11 20 minutes ago
RE-POST.....$TQQQ.... ...15. .....DLY... .BULL .Trend .HH, .....OPINION 12/06/2024

15...
https://schrts.co/xWKsmFyj

DLY....ZIG...
https://schrts.co/MrCuNesu
TQQQ
ds22 ds22 21 minutes ago
Some nice buying on HHSE on Friday. Been a little while since we have seen that sort of volume.
HHSE

Your Recent History

Delayed Upgrade Clock